Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas — (June 27, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and […]
de new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the […]
Original article: Acclaim-3 Dosing Begins: Quaratusugene Ozeplasmid/Atezolizumab in ES-SCLC (Targeted Oncology)
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors
Ryan Confer Appointed Genprex President and CEO and to its Board of Directors
AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024. Event: Sidoti Microcap Conference Conference Dates: May 8-9, 2024 […]
Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments
Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model